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Binding of glycopeptide antibiotics to a model of a
vancomycin-resistant bacterium
Matthew A Cooper and Dudley H Williams
Background: The vancomycin group of glycopeptide antibiotics is active
against a wide range of gram-positive bacteria. The increasing resistance to
vancomycin is the result of a change of an amide linkage (D-Ala–D-Ala) to an
ester linkage (D-Ala–D-Lactate) in the bacterial cell-wall precursors. 
Results: We have used a peptide terminating in the sequence -Lys–D-Ala–
D-Lactate linked by its amino terminus to a docosanoyl (C22) acyl chain and
anchored in a supported lipid monolayer to mimic the surface of vancomycin-
resistant enterococci. Surface plasmon resonance analysis was then used to
investigate the binding of glycopeptide group antibiotics to this surface.
Vancomycin, which dimerises weakly, bound with low affinity, whereas
strongly dimerising antibiotics, such as chloroeremomycin, bound with higher
affinities. Antibiotics that have attached hydrophobic groups, such as
teicoplanin and biphenylchloroeremomycin (LY307599), bound to the lipid
monolayer. This resulted in an enhanced affinity for the lipid-anchored
peptide at the surface relative to affinities for an analogous non-anchored
peptide in solution.
Conclusions: We have shown that the affinities of glycopeptide antibiotics
for a model of the surface of a vancomycin-resistant bacterium are enhanced
relative to affinities determined in free solution. We have also shown that
antibiotics that have membrane anchors bind tightly to the model surface and
that this feature is an important determinant of the ability of an antibiotic to kill
vancomycin-resistant enterococci.
Introduction
The vancomycin group of glycopeptide antibiotics is
active against a wide range of gram-positive bacteria, par-
ticularly those staphylococci and enterococci responsible
for postsurgical infections. The activity of the glycopep-
tide antibiotics (Figure 1) arises from their ability to bind
mucopeptide precursors terminating in the sequence
-Lys–D-Ala–D-Ala (-KAA) [1,2]. We have shown previ-
ously that, with the exception of teicoplanin, glycopeptide
antibiotics dimerise in aqueous solution [3] and that
dimerisation plays an important role in their biological
activity [4,5]. The molecular details of the vancomycin
dimer have been confirmed recently from X-ray crystal
structures [6,7]. We have proposed that glycopeptide
antibiotics are able to bind cooperatively as dimers to two
nascent mucopeptide chains at the bacterial membrane
surface, thereby disrupting cell-wall synthesis (Figure 2a). 
Unfortunately, resistance to vancomycin is now increasing
[8], and the accompanying increase in the number of
deaths from bacterial infections has given new urgency to
the search for novel antibiotics. This resistance is the result
of a deceptively simple change of an amide linkage to an
ester linkage in the bacterial cell-wall precursor lipid II
(undecaprenyl-pyrophosphoryl-MurNAc-[pentapeptide]-
GlcNAc) [9]. The change, conferred by substitution of the
terminal D-alanine of the cell-wall precursor with D-lactate,
results in a repulsive interaction within the binding pocket
of the antibiotic, and a consequent ~1000-fold decrease in
affinity, rendering the antibiotic therapeutically useless
[8–10]. Work by the groups of Griffin [11] and Whitesides
[12] has shown that covalently linked dimers of van-
comycin were more active against vancomycin-resistant
enterococci (VRE) by a factor of about 100 than was van-
comycin itself. Very recently, Uemura and coworkers [13]
have shown that a multivalent polymer of vancomycin also
shows activity against VRE. Whitesides and coworkers
have used self-assembled monolayers terminating in
D-Ala–D-Ala [14] and in D-Ala–D-lactate [12] together with
surface plasmon resonance (SPR) to show that the cova-
lently linked vancomycin dimer had a much higher
binding constant at a surface than in solution.
In previous studies, we have employed sodium dodecyl
sulfate micelles as model membranes to study the
binding interactions between antibiotic and peptide
ligands anchored to the lipid surface [15]. The small size
of the micelles allows nuclear magnetic resonance (NMR)
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analysis of antibiotic–peptide–micelle aggregates, but
their high radius of curvature and surfactant properties
makes them a poor membrane model. In this study, we
have used a peptide ligand terminating in the sequence
-Lys–D-Ala–D-Lactate, anchored in a supported lipid
monolayer by means of a C22 hydrocarbon tail
(Figure 2b). This peptide–lipid surface models the
mucopeptide precursors anchored in the membranes of
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Figure 1
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Figure 2
(a) Disruption of peptidoglycan synthesis by
binding of antibiotic dimer to nascent
mucopeptide on the surface of a vancomycin-
resistant bacterium. (b) Supported lipid
monolayer model of a bacterial membrane with
antibiotic dimer binding to the lipoyl peptide
N-α-docosanoyl-ε-acetyl-Lys–D-Ala–D-Lactate
(doc-KALac).
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vancomycin-resistant bacteria. Supported lipid monolay-
ers can be formed on an alkane-thiol self-assembled
monolayer, which is in turn mounted on a gold surface
[16]. The lipid monolayers formed in this way provide a
chemically and physically stable environment that resem-
bles the surface of a cellular membrane, and the gold
surface is suitable for SPR analysis [16,17]. Changes in
the measured refractive index at the interface, given in
response units (RU), are proportional to the amount of
material in the immediate vicinity of the sensor surface
[18]. Buffered solutions of an antibiotic can be passed
over the surface and the affinity of the binding event can
be calculated from analysis of the resultant binding curve.
Results and discussion
Formation of lipid and peptide–lipid monolayers
Supported lipid monolayers were formed from extruded
phosphatidylcholine vesicles on a hydrophobic self-assem-
bled monolayer, resulting in the deposition of ~2000 RU or
1.84 ng/mm2 (2.3 pmol/mm2) of lipid [17]. Coverage of the
surface with lipid was confirmed by the lack of nonspecific
binding of bovine serum albumin, which binds strongly to
the hydrophobic self-assembled monolayer alone
[17]. N-α-docosanoyl-ε-acetyl-Lys–D-Ala–D-Lactate (doc-
KALac) was then inserted into the lipid monolayer by
direct injection across lipid surfaces as a dilute solution
(data not shown). This resulted in the deposition of
~200 RU of doc-KALac, corresponding to a surface density
of ~0.18 ng/mm2 or 0.28 pmol/mm2 [17]. Studies using dif-
ferent radiolabelled proteins [18] have shown that there is
a linear relationship between the amount of absorbed
material and the SPR response. Although the sensitivity of
the SPR instrument is lower for absorbed species with
lower molecular weights, the instrument used for this work
has good sensitivity for molecular weights > 200 Da, and
the doc-KALac ligand has a molecular weight of 652 Da.
It could not be directly determined whether the doc-
KALac ligands inserted in the monolayer were mobile in
the plane of the lipid. Attempts to measure the diffusion
coefficient of a fluorescently labelled alkyl peptide
anchored in the lipid monolayer using fluorescence recov-
ery after photobleaching (FRAP) were unsuccessful, as the
fluorescence was quenched by the proximal gold film.
Recently, Plant [19] has reported that transferral of lipids
from a vesicle to a supported lipid monolayer has an effect
similar to that of reducing temperature: lipids in the mono-
layer were shown to have a similar degree of hydration and
temperature-dependent phase transitions to those
in a bilayer. Studies using peptides anchored in Lang-
muir–Blodgett films and supported lipid bilayers have
shown that the anchored molecules are homogeneously dis-
tributed in the lipid layer and have translational diffusion
coefficients in the order of 10–8 cm2/s [20,21]. Furthermore,
we have shown previously that doc-KAA inserted into
a supported lipid monolayer gives rise to enhanced 
antibiotic-binding constants consistent with an antibiotic
homodimer binding cooperatively to two ligands [22]. The
magnitude of the binding enhancements reported in the
current work is almost identical to that observed from a
competition NMR experiment using a lactate-terminating
peptide inserted into lipid vesicles [23]. In the light of these
similarities, and of the abundant evidence that molecules
are mobile in supported lipid bilayers and Langmuir–Blod-
gett films, we conclude that it is highly likely doc-KALac is
also mobile in the supported lipid monolayer.
The stability of the peptide–lipid layer was assayed by
flowing buffer at a flow rate of 20 µl/min across the surface
for 2 h (data not shown). The peptide was leached from
the lipid monolayer at a rate of 1.3 RU/min—a rate signif-
icantly faster than the drift observed for a lipid monolayer
alone (0.4 RU/min). Upon repeated injection of chloroere-
momycin across a doc-KALac-containing lipid monolayer,
the amount of antibiotic bound at equilibrium decreased
by 1% per cycle of binding and regeneration. To correct
for this effect, in addition to subtraction of data from the
flow cell containing lipid alone, data for binding to this
surface were further corrected by subtracting data result-
ing from an injection of buffer across the doc-KALac–lipid
surface. This extra correction resulted in a stable baseline
before the injection of antibiotic and resulted in repro-
ducible binding levels. We acknowledge that this type of
correction does not account for the fact that the surface
capacity is changing during the binding event and that this
effect can be accurately described by introducing extra
terms into the binding algorithm [24]. This was not done
because the drift, and the resultant reduction in surface
capacity, was very small. In addition, the corrected data
were not subjected to kinetic analysis and binding con-
stants were derived solely from examination of equilib-
rium binding levels at varying antibiotic concentration.
Antibiotics bind specifically to peptide-containing lipid
monolayers
With the exception of the lipophilic antibiotics teicoplanin
and biphenylchloroeremomycin (BCE), which bound to
lipid, all antibiotics showed extremely weak or negligible
binding to the control lipid surface (Figure 3). The rapid
change in response at the beginning and end of injection of
ristocetin A over the control lipid surface (Figure 3) is asso-
ciated with a bulk refractive index difference between the
antibiotic and buffer solutions. Binding of antibiotics to the
doc-KALac-containing surface was generally much weaker
than binding to a N-α-docosanoyl-lysyl(N-ε-acetyl)-D-
alanyl–D-alanine (doc-KAA)-containing surface [22]
(Figure 3). The affinity of vancomycin for the doc-KALac-
containing lipid monolayer (Ka ≤ 103 M–1) was 1000-fold
less than for the doc-KAA-containing lipid monolayer
(Ka = 1.4 × 106 M–1) [22]. The minimum inhibitory concen-
tration (MIC) values of vancomycin against VRE are up to
500-fold larger than for vancomycin-sensitive bacterial
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strains. These observations suggest that the doc-KALac-
and doc-KAA-containing lipid monolayers are reasonable
models of the surfaces of vancomycin-resistant and van-
comycin-sensitive bacteria, respectively.
With the exception of BCE and teicoplanin, data for
binding of the antibiotics to a lipid monolayer alone were
subtracted from data for binding to the doc-KALac-con-
taining surface to correct for bulk refractive index changes
between the antibiotic sample and the running buffer.
Regeneration of the free peptide was effected with 10 mM
hydrochloric acid without any apparent perturbation of the
peptide–lipid monolayer. TA3-1 and the weakly dimerising
antibiotics vancomycin and ristocetin A bound with
pseudo-first-order kinetics to the doc-KALac-containing
lipid monolayer. The strongly dimerising and lipid-anchor-
ing antibiotics bound in a biphasic manner. Kinetic analysis
of this complex behaviour will be discussed in a forthcom-
ing paper and in the present work affinities are derived
solely on the basis of analysis of equilibrium binding levels.
Gram-positive bacterial membranes are composed primar-
ily of phosphatidylglycerol, not of phosphatidylcholine.
Lipid monolayers were therefore formed both from
dimyristoylphosphatidylcholine (DMPC) and from di-
myristoylphosphatidylglycerol (DMPG). The affinities
calculated using the different types of lipid were very
similar (data not shown) and all data presented in this
paper result from experiments using phosphatidylcholine.
Correlation of affinities with dimerisation and
antimicrobial activity
Affinity constants of antibiotics for doc-KALac were deter-
mined by Scatchard analysis of binding levels at equilib-
rium for varying concentrations of antibiotic (Figure 4).
These affinities at a surface showed a moderately good
correlation (R = 0.87) with antimicrobial activity against
vancomycin-resistant bacteria (Table 1, Figure 5). This
correlation is similar to that between antibiotic affinities to
a doc-KAA–lipid monolayer and activity against van-
comycin-sensitive bacteria (R = 0.85) [17]. There was a
poor correlation between antibiotic dimerisation constants
(Kdim) and activity against vancomycin-resistant bacteria
(R = 0.48, data not shown), which is in contrast to the good
correlation between Kdim and activity against vancomycin-
sensitive bacteria (R = 0.90) [5]. This suggests that there
are factors other than dimerisation that are important
determinants of antibiotic activity against vancomycin-
resistant bacteria.
Binding of vancomycin to the doc-KALac–lipid layer was
too weak to be observed with the SPR instrument
employed, which is capable of measuring affinities
between 103 and 1012 M–1 [25]. Vancomycin binds weakly
to the surface and has a relatively high MIC value against
vancomycin-resistant bacteria because there is less coop-
erative benefit to be gained from cooperative binding to
two peptides at a surface when the antibiotic dimerises
to a smaller extent [26]. Chloroeremomycin, which
dimerises more strongly, bound with higher affinity to the
surface (Figure 5; Table 1). Like vancomycin, chloroere-
momycin had a low affinity for ac-KALac in solution, but
it is a strong dimeriser and therefore might be able to bind
cooperatively to two peptides templated on the surface.
The initial binding of peptide to one half of the dimer is
intermolecular, whereas binding to the other half of the
894 Chemistry & Biology 1999, Vol 6 No 12
Figure 3
Ristocetin A at 5 µM binding to a lipid monolayer alone (n), a lipid
monolayer containing 200 RU of doc-KALac (l) and a lipid monolayer
containing 200 RU of doc-KAA (l). The arrows indicate the beginning
and end of each injection.
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Figure 4
Binding of serial twofold dilutions of ristocetin A (65–4 µM) to a doc-
KALac-containing lipid monolayer. Data has been corrected for bulk
refractive index changes by subtraction of data for binding to a lipid
monolayer alone. The inset is a Scatchard plot of the data: Req is the
response in response units when the binding reaches equilibrium and
C is the concentration of vancomycin. A plot of Req versus Req/C has a
slope of –Ka (see the Materials and methods section for derivation).
Equilibrium binding levels for use in the Scatchard plot were
determined from extrapolation of binding curves to infinite time. 
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dimer at the surface is effectively intramolecular and
results in an affinity 1300-fold greater than that in solution
(Table 1). Chloroeremomycin also has a much lower MIC
value (Table 1). Using fluorinated peptides and 19F NMR
with phosphatidylcholine vesicles, we have previously
demonstrated that chloroeremomycin has a much higher
affinity for lactate-terminating peptides anchored in a
vesicle than for analogous ligands in free solution [27], but
the two values show a much smaller variation in the case
of vancomycin [23].
Eremomycin, which also dimerises strongly, bound with
only moderate affinity to the doc-KALac-containing
surface and bound more weakly than chloroeremomycin to
ac-KALac in solution (Table 1). Eremomycin differs from
chloroeremomycin in that it lacks a chlorine atom on the
aromatic residue 6 ring (Figure 1a). The chlorine atom at
this position has been shown in vancomycin to help define
the shape of the pocket into which the methyl group of
the binding peptide fits [28]. The chlorine atom con-
tributes to both the stability and the specificity of the
binding site, which may help explain why eremomycin
binds so poorly to the doc-KALac-containing surface and
why eremomycin has a 32-fold higher MIC value against
VRE than chloroeremomycin.
Ristocetin A, which dimerises weakly, was shown to bind
well to the doc-KALac surface (Table 1). The affinity of
Ristocetin A for ac-KALac in free solution, however,
could not be determined using UV difference spec-
troscopy or capillary electrophoresis. It is not known why
the surface binding constant of this weakly dimerising
antibiotic is relatively high, and in the absence of an accu-
rate value for the solution binding constant we are reluc-
tant to speculate further. TA3-1, which does not dimerise,
showed very weak affinity for the doc-KALac-containing
surface and the affinity to ac-KALac in free solution could
not be determined as no binding isotherm was observed
using UV difference spectrophotometry, even upon addi-
tion of a 10 mM solution of ac-KALac to a 50 µM solution
of the antibiotic. It is likely that the affinities are very
weak. Both TA3-1 and ristocetin A had poor activity
against VRE (Table 1).
Lipophilic antibiotics have enhanced affinities for the
doc-KALac surface
Teicoplanin is remarkable as it does not dimerise, yet it
has a surface-binding constant to doc-KALac 4200-fold
higher than that to ac-KALac in free solution. This is
because teicoplanin has a C11 acyl chain that functions as a
membrane anchor to localise the antibiotic at the surface
(Figure 1c) [4,15]. Binding to peptide in this case can be
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Table 1
Minimum inhibitory concentrations, dimerisation constants (Kdim) and affinity constants (Ka) of antibiotics for ac-KALac in solution
and for doc-KALac in a lipid monolayer.
MIC (µg/ml) 
Antibiotic E. faecium (207) Van A Kdim (M–1)* Ka (M–1) ac-KALac Ka (M–1) doc-KALac† ρsurf/soln‡
TA3-1 1024 < 1 n.d. 5.9 ± 0.3 × 104 n.d.
Vancomycin 512 700 410§ < 103 < 2.4
Ristocetin A 512 300 n.d. 1.5 ± 0.9 × 105 n.d.
Eremomycin 1024 4.0 × 105 70# 5.1 ± 0.9 × 104 730
CE 128¶ 1.6 × 104 240# 3.1 ± 0.4 × 105 1300
BCE 1¶ 2.0 × 105 350§ 5.8 ± 0.3 × 106 1.6 × 104
Teicoplanin 256 < 1 600 2.5 ± 0.3 × 106 4200
*From [22]; †In the case of teicoplanin and BCE the affinity describes
the interaction of the antibiotic with both the lipid monolayer and doc-
KALac (see text). ‡ρsurf/soln is defined as Ka (doc-KAA)/Ka (ac-KALac), a
measure of the enhancement gained by binding to ligand at the lipid
surface compared with binding to ligand in solution. §From [31]. #From
[41]. ¶Previously reported [42] average values against six strains of
VRE; CE, 32 µg/ml; BCE, 1 µg/ml.
Figure 5
Correlation between antimicrobial activity against E. faecium (207)
Van A and free energy of binding to doc-KALac in a lipid monolayer,
measured using SPR.
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cooperative as the antibiotic and peptide are attached to
the same template and the event is effectively intramolec-
ular, as is the case with the dimerising antibiotics. The
physical interpretation of the higher binding
(2.5 × 106 M–1) of teicoplanin to the model VRE surface is
not simple, because removing the antibiotic from the
surface requires its dissociation from the peptide and
removal of the hydrocarbon chain from the model mem-
brane. The high value obtained, however, is entirely con-
sistent with some surface cooperativity between
mucopeptide precursor binding and membrane anchoring
to improve its MIC value relative to TA3-1 against VRE
(Table 1). Similar arguments apply in the interpretation of
the data for the binding of biphenylchloroeremomycin
(Table 1, Figure 6; see below).
Several new semisynthetic glycopeptides have been dis-
covered recently that show activity against resistant strains
of bacteria in the order of 500 times greater than that of
vancomycin [29]. One such antibiotic, BCE (or
LY307599), has a biphenyl group attached synthetically to
the residue 4 epi-vancosamine sugar (Figure 1a). This
modification is remote from the known site of interaction
with cell-wall peptides and it is therefore not obvious why
it would have such an effect on the ability of the antibiotic
to kill bacteria.We have shown, however, that the affinity
for the –Lys–D-Ala–D-Ala sequence is not the only factor
determining antibiotic efficacy [4,5]. Membrane anchoring
in teicoplanin and dimerisation in chloroeremomycin
increase the effectiveness of these antibiotics. This
enhancement of activity arises through the ability of these
features to locate the antibiotic at its site of action—the
cell surface. The new antibiotic BCE has been shown to
dimerise strongly and the biphenyl moiety has been
shown to act as a membrane anchor [30,31]. We have
therefore hypothesised that the activity of this antibiotic is
due to membrane anchoring and dimerisation acting coop-
eratively to enhance greatly the low intrinsic affinity for
–D-lactate-terminating peptides found at the surface of
vancomycin-resistant bacteria.
The lipophilicity of BCE, teicoplanin and their analogues
lacking hydrocarbon appendages (CE and TA3-1) was
assayed. Both BCE and teicoplanin bound to a lipid
monolayer, whereas CE and TA3-1 did not bind signifi-
cantly. BCE showed an enhanced affinity for the doc-
KALac-containing surface relative to CE (Figure 6a,
Table 1). The affinity, or partitioning coefficient, of BCE
for lipid was calculated to be Kp = 3.6 × 106 M–1. The
affinity of teicoplanin for lipid was Kp = 2.3 × 106 M–1.
The biphenyl rings of BCE and the C11 alkyl chain of
teicoplanin were shown, using molecular modelling, to
contribute an extra 312 Å2 and 290 Å2 of hydrophobic
surface area, respectively, compared with the nonalky-
lated parent compounds. Using the solvent transfer value
of 0.125 kJ mol–1 Å–2 for the burial of hydrophobic surface
[32], this gives theoretical values for the burial of the
biphenyl rings of BCE and the acyl chain of teicoplanin
in hydrocarbon from water of 6.0 × 106 M–1 and
2.3 × 106 M–1, respectively. These values are reasonably
close to the Kp values determined experimentally.
BCE and teicoplanin have enhanced affinities for
doc-KALac inserted into a lipid monolayer relative to those
of the nonacylated analogues CE and TA31 (Table 1). It is
not possible in the case of BCE and teicoplanin to partition
what part of the binding energy results from interactions
with the lipid layer and what part from interactions with
doc-KALac as we can only measure the affinities for the
surface as a whole. Affinities were calculated from
Scatchard analysis of equilibrium binding levels and not by
kinetic analysis because many of the antibiotics did not
896 Chemistry & Biology 1999, Vol 6 No 12
Figure 6
(a) Binding of BCE at 5 µM to a lipid monolayer alone (n) and a
lipid–doc-KALac monolayer (l). Binding of chloroeremomycin at
5 µM to a lipid monolayer alone (×) and a lipid–doc-KALac monolayer
(l). (b) BCE at 5 µM binding to a lipid–doc-KALac monolayer (n,
solid line) together with the data fitted to the simple 1:1 Langmuir
binding algorithm (l, dashed line) and to the more complex two-step
binding algorithm (l, dashed line) described in the Materials and
methods section.
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bind with first-order kinetics. The deviation from first-
order kinetics was especially prominent in the case of the
strongly dimerising antibiotics and with BCE (Figure 6a).
Although the BCE-binding data could not be fitted using
algorithms describing a simple 1:1 Langmuir association, a
more complex algorithm describing successive binding to
the lipid layer, then to the lipid-bound doc-KALac (equa-
tions 4 and 5 in the Materials and methods section), fitted
the data well (Figure 6b). The faster association and disso-
ciation components of the biphasic binding curve were
described by K1 = ka1/kd1 and the slower phases by
K2 = ka2/kd2. This gave ka1 = 4400 M–1 s–1, kd1 = 0.032 s–1,
ka2 = 3.7 × 107 mol–1 cm2 s–1 kd2 = 0.0010 s–1 and thus
K1 = 1.4 × 105 M–1 and K2 = 3.7 × 1010 mol–1 cm2. The
second association rate constant (ka2) calculated from equa-
tion 5 (see the Materials and methods section) must be
expressed with two dimensional units (mol–1 cm2 s–1) as
the concentration of the initial complex bound to lipid
(AL) is calculated from equation 5 in terms of the observed
response. For this reason we cannot compare the rate and
affinity constants derived from the complex model directly
with those derived from a simple 1:1 kinetic analysis, and
we have instead used affinities calculated from simple
Scatchard analyses throughout this work.
Kahne and coworkers have recently reported data indicat-
ing that vancomycin group antibiotics that have lipophilic
moieties attached to the disaccharide portion of the antibi-
otic act primarily by inhibiting transglycosylation, but that
vancomycin itself primarily inhibits the subsequent
transpeptidation step [33]. Although we cannot preclude
that antibiotics carrying putative membrane anchors can
act in a different manner to vancomcyin, we note that
Reynolds [34] has concluded that vancomycin can inhibit
both transglycosylase and transpeptidase action. In addi-
tion, Allen et al. [35] have employed a strain of A. viridans
that synthesises, but does not cross-link, peptidoglycan, to
show that biosynthesis of non-cross-linked peptidoglycan
was inhibited by vancomycin. This is consistent with van-
comycin inhibiting the transglycosylation step, a hypothe-
sis that was supported by an observed accumulation of
lipid II intermediate.
Kahne and coworkers [33] also showed that a disaccharide
portion of vancomycin that has no -D-Ala–D-Ala binding
site, which was derivatised with a biphenyl lipophilic
anchor, was active against VRE, albeit at a MIC of
128 µg/ml. This is a striking finding, but, in the light of
the high MIC value relative to other lipophilic antibiotics
such as BCE, it is possible that the observed antimicrobial
activity arises from nonspecific inhibition of membrane-
associated glycosylases. There are numerous examples of
lipopeptides that interact with membranes and have
antibacterial activity. Many have surfactant activity and
cause nonspecific membrane disruption (e.g., subtilisin
and surfactin [36]), whereas others appear to be much
more specific in their action (e.g., amphomycin, dapto-
mycin, globomycin and ramoplanin [37]). In the light of
the differing conclusions regarding the peptidoglycan syn-
thesis step inhibited by vancomycin, and the possibility of
nonspecific activity of compounds lacking the -D-Ala–
D-Ala binding site, we note here our alternative hypothe-
ses without further speculation.
We propose that a membrane-anchoring chelate effect can
serve to enhance binding of antibiotics to cell-wall precur-
sors at a cell surface because both the antibiotic and its
target are attached by membrane anchors to the same tem-
plate, and the binding is therefore effectively intramolecu-
lar [15]. In accordance with the hypothesis that
dimerisation and membrane anchoring promote antibiotic
activity, it has been shown that these features make the
antagonism of antibiotic action by externally added ac-
KAA much more difficult [38]. We have also shown that
high surface-binding affinities are observed for binding of
the strongly dimerising antibiotic chloroeremomycin to
lactate-terminating peptides anchored in a supported lipid
monolayer (this work) and in lipid vesicles [23]. We there-
fore believe the remarkable activity of antibiotics such as
BCE against VRE is most likely due to two factors: an
enhanced ability to bind to -lactate terminating precursors,
which results in enhanced inhibition of bacterial transpep-
tidase, and localisation at the membrane surface, which
results in enhanced inhibition of bacterial transglycosylase.
Significance
Studies of cooperative interactions at surfaces have
important implications for the study of weak interactions
that occur between a drug and a receptor at the surface
of a cell membrane in general. We have shown that the
affinities of glycopeptide antibiotics for a model of the
surface of a vancomycin-resistant bacterium are
enhanced relative to those affinities determined in free
solution. We have also shown that antibiotics that have
membrane anchors bind tightly to the model surface and
that this feature is an important determinant of the ability
of an antibiotic to kill vancomycin-resistant enterococci.
Materials and methods
Octyl D-glucoside, bovine serum albumin, egg L-α-phosphatidyl-
choline, dimyristoylphosphatidylcholine and diglycerolphosphatidyl-
choline were purchased from Sigma-Aldrich (UK). The glycopeptide
antibiotics biphenylchloroeremomycin (LY307599), chloroeremomycin
(LY264826), eremomycin and vancomycin were a gift from Eli Lilly &
Co (Indianapolis, Ind., USA) Teicoplanin and teicoplanin aglycone
A3-1 were a gift from MMDR1 Lepetit Research Centre (Gerenzano,
Italy). Ristocetin A was obtained from Abbot Laboratories. The synthe-
sis of N,N-acetyl-lysyl-D-alanyl-D-lactic acid has been described previ-
ously [30]. The SPR instrument was a BIACORE 2000 (Biacore AB,
UK) used with a hydrophobic association (HPA) chip which consisted
of an octadecane-thiol self assembled monolayer on a gold surface.
Each sensor chip contained four flow cells of dimensions
2.4 × 0.5 × 0.05 mm (l × w × h) with a probing spot for the SPR signal
of ~0.26 mm2 for each flow cell. All experiments were carried out at
25°C with data points taken every 0.5 s.
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Determination of solution affinities by UV difference
spectroscopy
Binding constants between ac-KALac and antibiotics were carried out
on a UVIKON 940 dual beam spectrophotometer. Antibiotic and ligand
solutions were buffered with filtered, degassed phosphate buffer
(100 mM Na2HPO4/NaH2PO4, pH 7.4). Antibiotic were assayed at
50 µM with titrated ac-KALac solutions between 0.5 and 2 mM. The
λmax for the antibiotic–ligand complexes typically fell in the region of
290 nm. The concentration of antibiotic was kept constant during the
titration and ac-KALac was added in 10 µl aliquots. The solution was
stirred after each addition and the absorbance at λmax and at baseline
measured repeatedly until stable. The data at λmax were subtracted
from baseline values and the resulting data set analysed using a
simplex nonlinear least squares curve fitting program [39], which fits
the data to a simple 1:1 binding isotherm.
Organisms, growth media and MICs
E. faecium (207) Van A phenotype was a clinical isolate that was inocu-
lated in B. stearo broth and incubated overnight at 37°C. A sample of
the culture was then inoculated in fresh broth and incubated at 37°C for
1 h. 200 µl of the resultant mid-log phase cultures diluted to 106 cfu/ml
were then added to 96-well polystyrene tissue culture plates (Costar).
Antibiotics were then serially diluted twofold across the culture-contain-
ing wells from 1024 µg/ml to 0.5 µg/ml. The 96-well plates were than
covered and incubated with gentle shaking at 37°C overnight. MICs
were determined by inspection of broth turbidity after incubation.
Deposition of peptide–lipid monolayers
Phosphatidylcholine lipid monolayers were formed in filtered, degassed
phosphate buffer as described previously [17] on the first two cells of
an HPA sensor chip resulting in the deposition of ~2000 RU of lipid.
N-docosanoyl-lysyl(N-ε-acetyl)-D-alanyl–D-lactate (doc-KALac) was
then inserted into the lipid monolayer on the second flow cell of the
sensor chip by injection across the surface as a dilute solution (30 µl,
10 µl/min, 20 µM, freshly prepared from dry powder) in phosphate
buffer. The stability of the peptide in the lipid monolayer was assayed
by flowing buffer across the surface for 2 h at 20 µl/min.
Antibiotic–peptide binding assay
Serial twofold dilutions (65–2 µM) of the antibiotics vancomycin,
teicoplanin aglycone (TA3-1), ristocetin A, chloroeremomycin, ere-
momycin, teicoplanin and biphenylchloroeremomycin (LY307599) in
phosphate buffer were injected (60 µl, 20 µl/min) across a lipid mono-
layer alone and then across a doc-KALac–lipid monolayer with the
BIACORE instrument in multiflow cell mode. The antibiotic–peptide
complexes were allowed to dissociate for 4 min, then the free peptide
was regenerated by injection of hydrochloric acid (10 µl, 10 mM). Five
dummy runs of binding and regeneration were performed before data
acquisition. All assays were carried out at 25°C in duplicate.
Molecular modelling
The different antibiotic structures were modelled using MacroModel
3D GLX running on a Silicon Graphics Indy work station. Structures
were minimised in vacuo using the MM2 force field [40] and the
hydrophobic and hydrophilic surface areas of each were then calcu-
lated by applying a 1.4 Å water probe to the van der Waal surface of
the relevant subsets of each molecule.
SPR data analysis
Data were prepared for analysis by adjusting the response prior to
injection to zero and adjusting the time of each injection to zero. With
the exception of data for BCE and teicoplanin, which bound signifi-
cantly to lipid, data from the flow cell containing lipid alone was sub-
tracted from corresponding data obtained from the peptide-containing
flow cell to correct for bulk refractive index changes.
Affinities were calculated from analysis of equilibrium binding levels at
varying antibiotic concentration. When a binding curve had not
reached complete equilibrium, the equilibrium value was determined by
careful extrapolation of the binding curve. In the SPR flow cell, the
antibiotic is being continually added to and removed from the system
so the concentration will remain at the initial value, C. The total amount
of ligand present is expressed in terms of Rmax, the maximum possible
response. The amount of complex formed is proportional to Rt, the
observed response. Thus after a time, t, the concentration of antibiotic
will still be C, and the amount of free ligand will be given by Rmax–Rt:
ka
A + B AB (1)
kd
t = 0: C   Rmax 0
t = t: C  Rmax–Rt Rt
The association and dissociation rates, ka and kd, for formation of a
homogeneous binary complex of antibiotic A and ligand B in a SPR
flow cell are thus given by:
(2)
By measuring the resonance units attained at equilibrium (when by def-
inition dR/dt is zero), as a function of analyte concentration, affinities
can be determined from a Scatchard analysis using the equation:
(3)
where Req is the response at equilibrium and Ka is the association con-
stant (M–1). A plot of Req/C versus Req thus has a slope of –Ka.
The binding of an antibiotic to lipid (L) followed by binding to lipid-
bound ligand (B), is described by two response elements: R1, the
response due to the lipid-bound complex (AL) and R2, the response
due to the complex bound to both lipid and ligand (ALB), with both ele-
ments contributing to the total observed response: Rt = R1 + R2:
ka1 ka2
A + L + B AL + B ALB (4)
kd1 kd2
at t = 0: C Rmax1 0 Rmax2 0
at t = t: C Rmax1–R1–R2 R1 Rmax2–R2 R2
The kinetic rate constants are described by: 
(5)
where C is the concentration of antibiotic, Rmax1 is the maximum
binding capacity of the lipid layer and Rmax2 is the maximum binding
capacity of the ligand inserted in the lipid layer.
Supplementary material
Supplementary material including synthesis and 1H NMR assignments
for the peptide doc-KALac used in this study is available at
http://current-biology.com/supmat/supmatin.htm.
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